Anti-CRELD1 antibody (ab131286)
Key features and details
- Rabbit polyclonal to CRELD1
- Suitable for: WB, IHC-P
- Reacts with: Mouse, Rat, Human
- Isotype: IgG
Overview
-
Product name
Anti-CRELD1 antibody -
Description
Rabbit polyclonal to CRELD1 -
Host species
Rabbit -
Tested applications
Suitable for: WB, IHC-Pmore details -
Species reactivity
Reacts with: Mouse, Rat, Human
Predicted to work with: Horse, Cow, Dog, Pig, Chimpanzee, Macaque monkey, Gorilla, Orangutan
-
Immunogen
Synthetic peptide corresponding to Human CRELD1 aa 100-200 conjugated to keyhole limpet haemocyanin.
Database link: Q96HD1 -
Positive control
- This antibody gave a positive result in IHC in the following FFPE tissue: Human heart muscle. This antibody also gave a positive signal within WB in the following tissue lysates: Human Fetal Heart; Human Heart; Mouse Heart; Rat Heart.
-
General notes
Reproducibility is key to advancing scientific discovery and accelerating scientists’ next breakthrough.
Abcam is leading the way with our range of recombinant antibodies, knockout-validated antibodies and knockout cell lines, all of which support improved reproducibility.
We are also planning to innovate the way in which we present recommended applications and species on our product datasheets, so that only applications & species that have been tested in our own labs, our suppliers or by selected trusted collaborators are covered by our Abpromise™ guarantee.
In preparation for this, we have started to update the applications & species that this product is Abpromise guaranteed for.
We are also updating the applications & species that this product has been “predicted to work with,” however this information is not covered by our Abpromise guarantee.
Applications & species from publications and Abreviews that have not been tested in our own labs or in those of our suppliers are not covered by the Abpromise guarantee.
Please check that this product meets your needs before purchasing. If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, as well as customer reviews and Q&As.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.40
Preservative: 0.02% Sodium azide
Constituent: PBS
Batches of this product that have a concentration
Concentration information loading...Purity
Immunogen affinity purifiedClonality
PolyclonalIsotype
IgGResearch areas
Associated products
-
Compatible Secondaries
-
Isotype control
Applications
Our Abpromise guarantee covers the use of ab131286 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application Abreviews Notes WB Use a concentration of 1 µg/ml. Detects a band of approximately 45 kDa (predicted molecular weight: 45 kDa). IHC-P Use a concentration of 5 µg/ml. Target
-
Tissue specificity
Highly expressed in fetal lung, liver, kidney, adult heart, brain and skeletal muscle. Weakly expressed in placenta, fetal brain, and adult lung, liver, kidney and pancreas. -
Involvement in disease
Defects in CRELD1 may be the cause of susceptibility to atrioventricular septal defect type 2 (AVSD2) [MIM:606217]. AVSD is a spectrum of cardiac malformations that result in a persistent common atrioventricular canal. The complete form of AVSD involves underdevelopment of the lower part of the atrial septum and the upper part of the ventricular septum. A less severe form, known as partial AVSD or ostium primum atrial septal defect has a deficiency of the atrial septum. Complete AVSD are clinically apparent at birth, whereas less severe forms, such as an isolated cleft mitral valve or small defects of the atrial or ventricular septa may go undetected. -
Sequence similarities
Belongs to the CRELD family.
Contains 2 EGF-like domains.
Contains 2 FU (furin-like) repeats. -
Cellular localization
Membrane. - Information by UniProt
-
Database links
- Entrez Gene: 78987 Human
- Entrez Gene: 171508 Mouse
- Entrez Gene: 312638 Rat
- Omim: 607170 Human
- SwissProt: Q96HD1 Human
- SwissProt: Q91XD7 Mouse
- SwissProt: Q4V7F2 Rat
- Unigene: 9383 Human
see all -
Alternative names
- Atrioventricular septal defect 2 antibody
- AVSD2 antibody
- CIRRIN antibody
see all
Images
-
Western blot - Anti-CRELD1 antibody (ab131286)All lanes : Anti-CRELD1 antibody (ab131286) at 1 µg/ml
Lane 1 : Heart (Human) Whole Cell Lysate - fetal normal tissue
Lane 2 : Heart (Human) Tissue Lysate - adult normal tissue
Lane 3 : Heart (Mouse) Tissue Lysate
Lane 4 : Heart (Rat) Tissue Lysate
Lysates/proteins at 10 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/10000 dilution
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 45 kDa
Observed band size: 45 kDa
Additional bands at: 70 kDa (possible non-specific binding)
Exposure time: 4 minutesThis blot was produced using a 10% Bis-tris gel under the MOPS buffer system. The gel was run at 200V for 50 minutes before being transferred onto a Nitrocellulose membrane at 30V for 70 minutes. The membrane was then blocked for an hour using 5% Bovine Serum Albumin before being incubated with ab131286 overnight at 4°C. Antibody binding was detected using an anti-rabbit antibody conjugated to HRP, and visualised using ECL development solution.
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CRELD1 antibody (ab131286)IHC image of CRELD1 staining in Human heart muscle formalin fixed paraffin embedded tissue section, performed on a Leica BondTM system using the standard protocol F. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH6, epitope retrieval solution 1) for 20 mins. The section was then incubated with ab131286, 5µg/ml, for 15 mins at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.
For other IHC staining systems (automated and non-automated) customers should optimize variable parameters such as antigen retrieval conditions, primary antibody concentration and antibody incubation times.
Protocols
Datasheets and documents
References (0)
ab131286 has not yet been referenced specifically in any publications.
Images
-
Western blot - Anti-CRELD1 antibody (ab131286)All lanes : Anti-CRELD1 antibody (ab131286) at 1 µg/ml
Lane 1 : Heart (Human) Whole Cell Lysate - fetal normal tissue
Lane 2 : Heart (Human) Tissue Lysate - adult normal tissue
Lane 3 : Heart (Mouse) Tissue Lysate
Lane 4 : Heart (Rat) Tissue Lysate
Lysates/proteins at 10 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/10000 dilution
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 45 kDa
Observed band size: 45 kDa
Additional bands at: 70 kDa (possible non-specific binding)
Exposure time: 4 minutesThis blot was produced using a 10% Bis-tris gel under the MOPS buffer system. The gel was run at 200V for 50 minutes before being transferred onto a Nitrocellulose membrane at 30V for 70 minutes. The membrane was then blocked for an hour using 5% Bovine Serum Albumin before being incubated with ab131286 overnight at 4°C. Antibody binding was detected using an anti-rabbit antibody conjugated to HRP, and visualised using ECL development solution.
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CRELD1 antibody (ab131286)
IHC image of CRELD1 staining in Human heart muscle formalin fixed paraffin embedded tissue section, performed on a Leica BondTM system using the standard protocol F. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH6, epitope retrieval solution 1) for 20 mins. The section was then incubated with ab131286, 5µg/ml, for 15 mins at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.
For other IHC staining systems (automated and non-automated) customers should optimize variable parameters such as antigen retrieval conditions, primary antibody concentration and antibody incubation times.
